Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs

Muscle and Nerve

Volumn 46, Issue 5, 2012, Pages 773-784

  Serra, Filippo ^a   Quarta, Marco ^b,c   Canato, Marta ^d   Toniolo, Luana ^d   De Arcangelis, Valeria ^a   Trotta, Attilio ^a   Spath, Lucia ^a   Monaco, Lucia ^a   Reggiani, Carlo ^c,d   Naro, Fabio ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IIM Interuniversity Institute of Myology   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

COX; Glucocorticoids; Inflammation; Muscular dystrophy; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYTOKINE; IBUPROFEN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; UTROPHIN;

ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; FATIGUE; GENE EXPRESSION; HISTOPATHOLOGY; MACROPHAGE; MALE; MORPHOLOGY; MOUSE; MUSCLE CELL; MUSCLE TONE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIAPHRAGM; DISEASE PROGRESSION; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCULAR DYSTROPHIES; TREATMENT OUTCOME;

EID: 84867366583     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23432     Document Type: Article

References (52)

1. DeSilva S, Drachman DB, Mellits D, Kuncl RW. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol 1987; 44: 818-22.
2. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320: 1592-1597.
3. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT III, Griggs RC, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41: 1874-1877.
4. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, et al. Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice. Res Commun Chem Pathol Pharmacol 1993; 79: 45-60.
5. Keeling RM, Golumbek PT, Streif EM, Connolly AM. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 2007; 35: 43-48.
6. De Luca A, Pierno S, Liantonio A, Conte Camerino D. Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness. Neuromuscul Disord 2002; 12(suppl 1): S142-146.
7. Weller B, Massa R, Karpati G, Carpenter S. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 1991; 14: 771-774.
8. Golumbek PT, Keeling RM, Connolly AM. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 2007; 17: 376-384.
9. Griggs RC, Moxley RT III, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Duchenne dystrophy: randomized controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43: 520-527.
10. Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT III, et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 1993; 43: 532-536.
11. Wissing ER, Millay DP, Vuagniaux G, Molkentin JD. Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord 2010; 20: 753-760.
12. Jacobs SC, Bootsma AL, Willems PW, Bär PR, Wokke JH. Prednisone can protect against exercise-induced muscle damage. J Neurol 1996; 243: 410-416.
13. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, Knudson JC, Jasmin BJ, Megeney LA. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 2004; 18: 1937-1939.
14. Fisher I, Abraham D, Bouri K, Hoffman EP, Muntoni F, Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J 2005; 19: 834-836.
15. Collins CA, Morgan JE. Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003; 84: 165-172.
16. McGeachie JK, Grounds MD. The timing between skeletal muscle myoblast replication and fusion into myotubes, and the stability of regenerated dystrophic myofibres: an autoradiographic study in mdx mice. J Anat 1999; 194: 287-295.
17. Grounds MD, McGeachie JK. Skeletal muscle regeneration after crush injury in dystrophic mdx mice: an autoradiographic study. Muscle Nerve 1992; 15: 580-586.
18. Peluffo GD, Stillitani I, Rodríguez VA, Diament MJ, Klein SM. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 2004; 110: 825-830.
19. Reuter BK, Zhang XJ, Miller MJ. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer 2002; 9: 2-19.
20. Liles JH, Flecknell PA. The use of non-steroidal anti-inflammatory drugs for the relief of pain in laboratory rodents and rabbits. Lab Anim 1992; 26: 241-255.
21. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005; 83: 171-181.
22. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 2002; 200: 69-79.
23. Stauber WT, Fritz VK, Vogelbach DW, Dahlmann B. Characterization of muscles injured by forced lengthening. I. Cellular infiltrates. Med Sci Sports Exerc 1988; 20: 345-353.
24. Jiang D, Schwarz H. Regulation of granulocyte and macrophage populations of murine bone marrow cells by G-CSF and CD137 protein. PloS One 2010; 5: e15565.
25. De Arcangelis V, Serra F, Cogoni C, Vivarelli E, Monaco L, Naro F. β1-syntrophin modulation by miR-222 in mdx mice. PLoS One 2010; 5: e12098.
26. Rossi R, Bottinelli R, Sorrentino V, Reggiani C. Response to caffeine and ryanodine receptor isoforms in mouse skeletal muscles. Am J Physiol Cell Physiol 2001; 281: C585-594.
27. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004; 18: 676-682.
28. Moghadaszadeh B, Albrechtsen R, Guo LT, Zaik M, Kawaguchi N, Borup RH, et al. Compensation for dystrophin-deficiency: ADAM12 overexpression in skeletal muscle results in increased alpha 7 integrin, utrophin and associated glycoproteins. Hum Mol Genet 2003; 12: 2467-2479.
29. Davies KE, Grounds MD. Treating muscular dystrophy with stem cells? Cell 2006; 127: 1304-1306.
30. Trollet C, Athanasopoulos T, Popplewell L, Malerba A, Dickson G. Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther 2009; 9: 849-866.
31. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-421.
32. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157: 137-148.
33. Blaauw B, Mammucari C, Toniolo L, Agatea L, Abraham R, Sandri M, et al. Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum Mol Genet 2008; 17: 3686-3696.
34. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000; 10: 235-239.
35. Coulton GR, Morgan JE, Partridge TA, Sloper JC. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 1988; 14: 53-70.
36. Randall CL, Becker HC, Anton RF. Effect of ibuprofen on alcohol-induced teratogenesis in mice. Alcohol Clin Exp Res 1991; 15: 673-677.
37. Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010; 11: 1-26.
38. Mackey AL, Kjaer M, Dandanell S, Mikkelsen KH, Holm L, Døssing S, et al. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol 2007; 103: 425-431.
39. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 2007; 104: 264-269.
40. Anderson JE, Weber M, Vargas C. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant 2000; 9: 551-564.
41. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 2001; 535: 591-600.
42. Stevens ED, Faulkner JA. The capacity of mdx mouse diaphragm muscle to do oscillatory work. J Physiol 2000; 522: 457-66.
43. Gregorevic P, Plant DR, Leeding KS, Bach LA, Lynch GS. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-1 administration. Am J Pathol 2002; 161: 2263-2272.
44. Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clin Exp Pharmacol Physiol 2008; 35: 725-729.
45. Wilcox PG, Hards JM, Bockhold K, Bressler B, Pardy RL. Pathologic changes and contractile properties of the diaphragm in corticosteroid myopathy in hamsters: comparison to peripheral muscle. Am J Respir Cell Mol Biol 1989; 1: 191-199.
46. Moore BJ, Miller MJ, Feldman HA, Reid MB. Diaphragm atrophy and weakness in cortisone-treated rats. J Appl Physiol 1989; 67: 2420-2426.
47. Petrof BJ, Stedman HH, Shrager JB, Eby J, Sweeney HL, Kelly AM. Adaptations in myosin heavy chain expression and contractile function in dystrophic mouse diaphragm. Am J Physiol 1993; 265: C834-841.
48. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008; 31: 1-19.
49. Hirst RC, McCullagh KJ, Davies KE. Utrophin upregulation in Duchenne muscular dystrophy. Acta Myol 2005; 24: 209-216.
50. Chakkalakal JV, Thompson J, Parks RJ, Jasmin BJ. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J 2005; 19: 880-891.
51. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; 23: CD003725.
52. Wehling-Henricks M, Lee JJ, Tidball JG. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul Disord 2004; 14: 483-490.